Delonix Bioworks


Delonix Bioworks is a synthetic biology start-up that focuses on the development of innovative bacterial vaccines. The company was founded in 2021 and is headquartered in Shanghai, China. Delonix has closed a $14 million Series Seed financing round, led by Boehringer Ingelheim Venture Fund (BIVF) and IDG Capital, and championed the first Boehringer Ingelheim Innovation Prize in China.
Within two years, Delonix has developed comprehensive toolkits for efficient strain engineering on more than 10 common pathogens. The company has also launched two proprietary synthetic vaccine platforms - ProBVax and BioDVax - to expedite the development of various types of bacterial vaccines. These platforms have resulted in the generation of over five innovative vaccine pipelines. Notably, the lead assets DX-101 (Staphylococcus aureus vaccine) and DX-104 (MenB vaccine) expected to undergo IND application in 2025.
Find out more at